4.6 Review

The effects of kefir consumption on human health: a systematic review of randomized controlled trials

Journal

NUTRITION REVIEWS
Volume 81, Issue 3, Pages 267-286

Publisher

OXFORD UNIV PRESS INC
DOI: 10.1093/nutrit/nuac054

Keywords

cultured milk products; dairy products; gut microbiome; kefir; microbiome; oral microbiome; probiotics

Ask authors/readers for more resources

Fermented-milk kefir may have potential health benefits, such as reducing the risk of dental caries, eradicating Helicobacter pylori, and aiding in the treatment of adult dyslipidemia and hypertension. However, the available evidence is limited, and more high-quality human trials are needed to determine its efficacy and safety.
Context Kefir, a traditional, fermented-milk beverage, has increasingly been promoted for various health benefits. The evidence from systematic reviews, however, is limited. Objective Evidence from randomized controlled trials testing oral consumption of fermented-milk kefir on any outcome of human health or disease. Data Sources A systematic search of 4 electronic databases (PubMed, Scopus, Allied and Complementary Medicine Database, and Cochrane Trials) from inception to July 31, 2021, was conducted. Data Extraction Data extraction and risk-of-bias assessments were conducted by 2 reviewers independently. Data Analysis A total of 18 publications reporting the results of 16 studies were included. Per the narrative analysis, fermented-milk kefir may have potential as a complementary therapy in reducing oral Streptococcus mutans, thereby reducing dental caries risk, and in Helicobacter pylori eradication therapy. Kefir may further aid treatment of adult dyslipidemia and hypertension, although evidence was very limited. Safety was only assessed in 5 of the 18 included publications, and 12 of the studies had an overall high risk for bias. Conclusion Kefir is a dairy product with a unique microbiological profile that appears to be a safe for generally healthy populations to consume. However, efficacy and safety data from high-quality human trials are essential before any recommendations may be made for conditions of the oral and gastric microbiota and metabolic health. Systematic review registration PROSPERO registration no. CRD42020211494.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available